Thymia has raised a £780k/$1.1m pre-seed round to scale its platform to assess for and monitor depression. The Thymia technology removes the subjectivity from mental health assessments: instead of answering questionnaires, patients play specially designed video games which use cutting-edge Neuropsychology, Linguistics and Machine Learning to detect signs of depression, as well as monitor whether symptoms are improving or worsening over time. 

Turquoise, the UK merchant bank specialising in energy, environment and efficiency, has invested in Ablatus Therapeutics for the Low Carbon Innovation Fund 2 (LCIF2). The investment of £85,000 is part of an overall round which could reach £1.5 million.

Ablatus Therapeutics is developing Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques, in order to offer greater clinical options and to improve patient outcomes. 

Epipole, the video retinal imaging specialist, has started work on a €1.1 million collaborative project to develop a technology solution for the diagnosis of intracranial pressure (ICP). The project is funded by the Eureka Eurostars programme, and is a collaboration between Epipole, Denmark’s Statumanu ICP and the University of Southern Denmark.

Foresight Group has invested 3 million of growth capital into NorthWest EHealth Limited, providers of software and services to the clinical trials market.

Navenio, the UK company that has pioneered indoor location-based artificial intelligence to revolutionise workflows and can double the throughput of hospital teams, has been successful in securing funding in the latest round of the Artificial Intelligence in Health and Care Award.

Foresight Group has made a £300,000 growth capital investment from the Midlands Engine Investment Fund (MEIF) into ReadyGo Diagnostics Limited, a start-up diagnostics business. 

UK-based healthtech firm Kiteline, formerly known as Liminal Health, has secured £370,000 in funding to meet the demand for support for those living with chronic conditions, including cancer, diabetes, heart disease, and, most recently, long COVID.

Palatine Private Equity has acquired a majority stake in Routes Healthcare, one of the North’s leading providers of specialist person-centred health and homecare services. Headquartered in the North-West, the business operates from 14 service centres, employing 120 operational and management staff, along with 1,000 carers.

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, has raised $9.6M seed financing led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek. The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets.

Hertility Health, the new women’s health start-up revolutionising the world of hormone and reproductive health, has announced the closing of a £4.2 million Seed funding round led by LocalGlobe - one of the UK's most prolific seed investors, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.

Iceni Diagnostics, a specialist carbohydrate chemistry company based in Norwich, which raised funds in November 2020 from RAB Capital and Angel investors, has agreed an exclusive global licence, to integrate key virus detection intellectual property (IP) developed by the University of Warwick, into its commercial diagnostics programmes.

Fertility Focus, the manufacturers of the OvuCore and OvuSense Pro family of leading fertility monitoring solutions, with class II medical device classification and 510k FDA clearance – has launched OvuFirst, a completely unique patented sensor designed to measure skin temperature, providing women with an understanding of when to try and conceive naturally, and enabling them to determine what issues they may have trying to conceive. Foresight Group has been a strategic partner with Fertility Focus since their £1.25 million investment in 2019.